OpenAlex
PricingAboutJobs
Log inGet started
Work

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

HTML

Year: 2019
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-18-1203
Authors: Drew W. Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent Shih
Institutions: South Texas Accelerated Research Therapeutics, Celgene (United States), Institute of Cancer Research, Sarah Cannon, Tennessee Oncology
Language: English

Topic: Protein Degradation and Inhibitors
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: cereblon E3 ligase, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, non-Hodgkin lymphoma, multiple myeloma, solid tumors, brain cancer, neutropenia, immunomodulation
SDG: Good health and well-being

Open Access status: closed

Funders: Celgene, Cancer Research UK
Awards: G3601372966, G662952953
OpenAlex ID: W2891958511
FWCI: 4.393
Cites: 29
Cited by: 100
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security